Alexandra, Countess of Frederiksborg

Launch of two first-in-class medicines in 2023 marks start of exciting phase of growth for Ferring

Retrieved on: 
星期二, 四月 9, 2024
Research, Clinical Trials, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, CER, Nadofaragene firadenovec, AER, Audit, Growth, Alexandra, Countess of Frederiksborg, Ferring, Falk, Partnership, ESG, Mortality, Nordic Investment Bank, PPH, Committee on Finance, Annual report, Count, Vice, Food, Management

EBITDA increased by +€43 million (+12% at AER) to reach €406 million and operating profit for the year reached €139 million.

Key Points: 
  • EBITDA increased by +€43 million (+12% at AER) to reach €406 million and operating profit for the year reached €139 million.
  • The year marked a major turning-point for Ferring with the launch of two innovative first-in-class medicines in the United States.
  • Ferring is evolving to make the most of these opportunities, and there were a number of significant changes to the senior leadership.
  • Jean-Frédéric Paulsen, Chairman of the Board of Directors, said: “The launch of two groundbreaking medicines in the US, along with the other important changes in 2023, mark the start of an exciting new phase of growth for Ferring.

Ferring Pharmaceuticals appoints new Executive Chairman among key changes to Board of Directors

Retrieved on: 
星期四, 六月 22, 2023
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, FDA, Clinical Trials, Clostridioides difficile infection, Danske Bank, Ferring Pharmaceuticals, Alexandra, Countess of Frederiksborg, US Foods, Reproductive medicine, Clostridioides, Audit, Food, Senior advisor, Center for Biologics Evaluation and Research, Nadofaragene firadenovec, Bladder cancer, Count, Medicine, Credit Suisse, Coca-Cola, Maternal health, Nordic Investment Bank, BCG, Novartis, Control, Mars, Incorporated, London, Growth, Recurrence, Sustainable development, Committee on Finance, Chartered Institute of Management Accountants, Wyeth, London School of Economics, Pharmaceutical industry, Management, Nordic, Economics

Lars Rebien Sørensen, who became Executive Chairman in July 2021, will remain on the Board as Vice-Chairman.

Key Points: 
  • Lars Rebien Sørensen, who became Executive Chairman in July 2021, will remain on the Board as Vice-Chairman.
  • Mr. Paulsen’s father, Dr. Frederik Paulsen, who held the post of Chairman from 1988 until 2021, continues as Chairman Emeritus of the Ferring Group.
  • At the same time, Jeffrey Hobbs and Alexandra, Countess of Frederiksborg have stood down from the Board of Directors.
  • Mr. Sørensen said: “As Vice-Chairman of the Board of Directors, I am pleased to support the new Executive Chairman during a period of transition as he takes on greater responsibilities from the Chairman Emeritus.